Back to News
Feb 12, 2026 12:50 PM

BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026

BridgeBio Pharma Inc. (NASDAQ:BBIO) stock is surging on Thursday and nearing the upper end of its 52-week range of $28.33-$84.94, according to Benzinga Pro data.

The biopharmaceutical company focused on genetic conditions, shared positive topline results from PROPEL 3 Phase 3 pivotal study of oral infigratinib in children with achondroplasia, the most common form of skeletal dysplasia leading to disproportionate short-limb dwarfism.

PROPEL 3 evaluated infigratinib in children with achondroplasia aged 3 to 18 years with open growth plates.

Key Results

Change from baseline in annualized height velocity (AHV) superior to placebo, with an LS mean treatment difference of +1.74 cm/year and a mean treatment difference of +2.10 cm/year

The secondary endpoint of absolute AHV at week 52 showed a significant improvement with infigratinib compared to placebo, with the infigratinib arm achieving the highest LS mean absolute AHV reported to date in a randomized trial in achondroplasia (5.96 cm/year versus 4.22 cm/year on placebo).

In a pre-specified exploratory analysis (children younger than 8; more than ...